<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37779307</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1941-5923</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><PubDate><Year>2023</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>The American journal of case reports</Title><ISOAbbreviation>Am J Case Rep</ISOAbbreviation></Journal><ArticleTitle>A Rare Case of Subcutaneous Amyloidoma Associated with Localized Lymphoplasmacytic Lymphoma: Diagnostic Challenges and Treatment Considerations.</ArticleTitle><Pagination><StartPage>e940789</StartPage><MedlinePgn>e940789</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/AJCR.940789</ELocationID><Abstract><AbstractText>BACKGROUND AL amyloidomas are solitary, localized, tumor-like deposits of immunoglobulin light-chain-derived amyloid fibrils in the absence of systemic amyloidosis. A rare entity, they have been described in various anatomical sites, typically in spatial association with a sparse lymphoplasmacytic infiltrate, ultimately corresponding to a clonal, malignant, lymphomatous disorder accounting for the amyloidogenic activity. Most frequently, the amyloidoma-associated hematological disorder corresponds to either a solitary plasmacytoma or an extranodal marginal zone lymphoma of MALT. Much rarer is the association with lymphoplasmacytic lymphoma, which by itself is usually a bone marrow-bound disorder with systemic burden. The almost anecdotic combination of an amyloidoma and a localized lymphoplasmacytic lymphoma deserves attention, as it entails a thorough diagnostic workup to exclude systemic involvement and a proportionate therapeutic approach to avoid overtreatment. A review of the literature provides an insight on pathogenesis and prognosis, and can assist both pathologists and clinicians in establishing optimal patient management strategies. CASE REPORT We herein report the incidental finding of a subcutaneous amyloidoma caused by a spatially related, similarly localized lymphoplasmacytic lymphoma diagnosed in a 54-year-old female patient with no other disease localizations and a complete remission following 2 subsequent surgical excisions. CONCLUSIONS Whatever the specific combination of an amyloidoma and the related hematological neoplasm, a multidisciplinary collaboration and a comprehensive clinical-pathological staging are warranted to exclude systemic involvement and identify patients with localized diseases who would benefit from local active treatment and close follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vivian</LastName><ForeName>Lisa Francesca</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0001-6836-6525</Identifier><AffiliationInfo><Affiliation>Department of Pathology, ASST Santi Paolo e Carlo, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcelis</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5446-1801</Identifier><AffiliationInfo><Affiliation>Department of Pathology, UZ Leuven, University Hospitals, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Translational Cell and Tissue Research Lab, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, ASST Valle Olona, Busto Arsizio, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bruecker</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Imelda Hospital, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imelda Hospital, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierr&#xe9;</LastName><ForeName>Erwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Imelda Hospital, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballaux</LastName><ForeName>Florence M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Imelda Hospital, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tousseyn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0397-1086</Identifier><AffiliationInfo><Affiliation>Department of Pathology, UZ Leuven, University Hospitals, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Translational Cell and Tissue Research Lab, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Case Rep</MedlineTA><NlmUniqueID>101489566</NlmUniqueID><ISSNLinking>1941-5923</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018442" MajorTopicYN="Y">Lymphoma, B-Cell, Marginal Zone</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008258" MajorTopicYN="Y">Waldenstrom Macroglobulinemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010954" MajorTopicYN="Y">Plasmacytoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012983" MajorTopicYN="Y">Soft Tissue Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37779307</ArticleId><ArticleId IdType="pmc">PMC10556539</ArticleId><ArticleId IdType="doi">10.12659/AJCR.940789</ArticleId><ArticleId IdType="pii">940789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022;29(4):213&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">36420821</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuhlmann-Laeisz C, Schonland SO, Hegenbart U, et al. AL amyloidosis with a localized B cell neoplasia. Virchows Arch. 2019;474(3):353&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30680453</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagannathan G, Uppal G, Judy K, Curtis MT. Cerebral amyloidoma resulting from central nervous system lymphoplasmacytic lymphoma: a case report and literature review. Case Rep Pathol. 2018;2018:5083234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6038588</ArticleId><ArticleId IdType="pubmed">30046502</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace AA, Lownes SE, Shivane A, et al. A tale of the unexpected: amyloidoma associated with intracerebral lymphoplasmacytic lymphoma. J Neurol Sci. 2015;359(1&#x2013;2):404&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellie E, Vergier B, Duche B, et al. Local amyloid deposits in a primary central nervous system lymphoma. Study of a stereotactic brain biopsy. Clin Neuropathol. 1990;9(5):231&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">2125534</ArticleId></ArticleIdList></Reference><Reference><Citation>Badell A, Servitje O, Graells J, et al. Salivary gland lymphoplasmacytoid lymphoma with nodular cutaneous amyloid deposition and lambda chain paraproteinemia. Br J Dermatol. 1996;135(2):327&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8881687</ArticleId></ArticleIdList></Reference><Reference><Citation>Per Westermark Localized AL amyloidosis: A suicidal neoplasm? Ups J Med Sci. 2012;117(2):244&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339556</ArticleId><ArticleId IdType="pubmed">22335280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>